Published in Nat Biotechnol on December 01, 2007
A three-dimensional view of the molecular machinery of RNA interference. Nature (2009) 6.31
Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet (2009) 3.09
Antiviral RNA interference in mammalian cells. Science (2013) 2.89
The evolution of RNAi as a defence against viruses and transposable elements. Philos Trans R Soc Lond B Biol Sci (2009) 2.35
Human cellular restriction factors that target HIV-1 replication. BMC Med (2009) 1.86
RNA-based viral immunity initiated by the Dicer family of host immune receptors. Immunol Rev (2009) 1.82
Pyrosequencing of small non-coding RNAs in HIV-1 infected cells: evidence for the processing of a viral-cellular double-stranded RNA hybrid. Nucleic Acids Res (2009) 1.69
Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res (2008) 1.65
Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming. J Biol Chem (2010) 1.59
Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference. J Virol (2007) 1.50
Deep sequencing of virus-infected cells reveals HIV-encoded small RNAs. Nucleic Acids Res (2011) 1.32
RNA viruses and the host microRNA machinery. Nat Rev Microbiol (2013) 1.31
Elimination of antiviral defense by viral RNase III. Proc Natl Acad Sci U S A (2009) 1.29
Rationalizing the development of live attenuated virus vaccines. Nat Biotechnol (2010) 1.26
MicroRNAs and the regulation of vector tropism. Mol Ther (2008) 1.25
Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol Ther (2009) 1.18
Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther (2012) 1.10
Sustained delivery of siRNAs targeting viral infection by cell-degradable multilayered polyelectrolyte films. Proc Natl Acad Sci U S A (2008) 1.09
HIV evades RNA interference directed at TAR by an indirect compensatory mechanism. Cell Host Microbe (2008) 1.07
Origins of alphavirus-derived small RNAs in mosquitoes. RNA Biol (2009) 1.06
Molecular evolution of a viral non-coding sequence under the selective pressure of amiRNA-mediated silencing. PLoS Pathog (2009) 1.06
Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs. Retrovirology (2010) 1.05
Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond) (2010) 1.05
RNAi in the regulation of mammalian viral infections. BMC Biol (2012) 1.04
HIV develops indirect cross-resistance to combinatorial RNAi targeting two distinct and spatially distant sites. Mol Ther (2012) 1.01
Tat RNA silencing suppressor activity contributes to perturbation of lymphocyte miRNA by HIV-1. Retrovirology (2011) 0.99
RNAi: antiviral therapy against dengue virus. Asian Pac J Trop Biomed (2013) 0.97
Artificial riboswitches for gene expression and replication control of DNA and RNA viruses. Proc Natl Acad Sci U S A (2014) 0.96
MicroRNA regulation of human protease genes essential for influenza virus replication. PLoS One (2012) 0.96
Learning from the messengers: innate sensing of viruses and cytokine regulation of immunity - clues for treatments and vaccines. Viruses (2013) 0.95
Regulation of microRNA biogenesis and turnover by animals and their viruses. Cell Mol Life Sci (2013) 0.95
Current progress in the development of RNAi-based therapeutics for HIV-1. Gene Ther (2011) 0.93
The A-rich RNA sequences of HIV-1 pol are important for the synthesis of viral cDNA. Nucleic Acids Res (2008) 0.92
VIRsiRNAdb: a curated database of experimentally validated viral siRNA/shRNA. Nucleic Acids Res (2011) 0.92
Titers of lentiviral vectors encoding shRNAs and miRNAs are reduced by different mechanisms that require distinct repair strategies. RNA (2010) 0.92
HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms. Philos Trans R Soc Lond B Biol Sci (2010) 0.90
Silencing early viral replication in macrophages and dendritic cells effectively suppresses flavivirus encephalitis. PLoS One (2011) 0.89
Inactivation of the type I interferon pathway reveals long double-stranded RNA-mediated RNA interference in mammalian cells. EMBO J (2016) 0.89
The VP3 factor from viruses of Birnaviridae family suppresses RNA silencing by binding both long and small RNA duplexes. PLoS One (2012) 0.88
Silencing viral microRNA as a novel antiviral therapy? J Biomed Biotechnol (2009) 0.88
Replication competent HIV-1 viruses that express intragenomic microRNA reveal discrete RNA-interference mechanisms that affect viral replication. Cell Biosci (2011) 0.87
Multiple shRNA combinations for near-complete coverage of all HIV-1 strains. AIDS Res Ther (2011) 0.87
Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1. BioDrugs (2012) 0.87
RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? Expert Opin Biol Ther (2010) 0.87
Effects of the knockdown of hypoxia inducible factor-1α expression by adenovirus-mediated shRNA on angiogenesis and tumor growth in hepatocellular carcinoma cell lines. Korean J Hepatol (2010) 0.86
RNAi-mediated inhibition of HIV-1 by targeting partially complementary viral sequences. Nucleic Acids Res (2009) 0.86
Sequence recombination and conservation of Varroa destructor virus-1 and deformed wing virus in field collected honey bees (Apis mellifera). PLoS One (2013) 0.86
RNA interference against animal viruses: how morbilliviruses generate extended diversity to escape small interfering RNA control. J Virol (2011) 0.85
Broad-spectrum antiviral activity of RNA interference against four genotypes of Japanese encephalitis virus based on single microRNA polycistrons. PLoS One (2011) 0.83
Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery. Antiviral Res (2012) 0.83
Human U6 promoter drives stronger shRNA activity than its schistosome orthologue in Schistosoma mansoni and human fibrosarcoma cells. Transgenic Res (2011) 0.83
Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo. Int J Mol Sci (2015) 0.82
Induction and suppression of antiviral RNA interference by influenza A virus in mammalian cells. Nat Microbiol (2016) 0.81
Selection of RNAi-based inhibitors for anti-HIV gene therapy. World J Virol (2012) 0.81
Localization and sub-cellular shuttling of HTLV-1 tax with the miRNA machinery. PLoS One (2012) 0.81
Antiviral Stratagems Against HIV-1 Using RNA Interference (RNAi) Technology. Evol Bioinform Online (2013) 0.81
An adenoviral vector-based expression and delivery system for the inhibition of wild-type adenovirus replication by artificial microRNAs. Antiviral Res (2012) 0.80
Small regulatory RNAs in Archaea. RNA Biol (2014) 0.80
RNA interference targeting virion core protein ORF095 inhibits Goatpox virus replication in Vero cells. Virol J (2012) 0.80
How many antiviral small interfering RNAs may be encoded by the mammalian genomes? Biol Direct (2010) 0.80
VIRsiRNApred: a web server for predicting inhibition efficacy of siRNAs targeting human viruses. J Transl Med (2013) 0.79
RNA Viruses and RNAi: Quasispecies Implications for Viral Escape. Viruses (2015) 0.78
ESF-EMBO symposium: antiviral applications of RNA interference. Retrovirology (2008) 0.78
A novel ribozyme-based prophylaxis inhibits influenza A virus replication and protects from severe disease. PLoS One (2011) 0.78
Evaluation of canonical siRNA and Dicer substrate RNA for inhibition of hepatitis C virus genome replication--a comparative study. PLoS One (2015) 0.77
Mosquito-borne viruses and suppressors of invertebrate antiviral RNA silencing. Viruses (2014) 0.77
Arginine rich short linear motif of HIV-1 regulatory proteins inhibits dicer dependent RNA interference. Retrovirology (2013) 0.77
Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer. J Clin Med (2015) 0.76
RNAi Efficiency, Systemic Properties, and Novel Delivery Methods for Pest Insect Control: What We Know So Far. Front Physiol (2016) 0.76
Selection of the most potent specific on/off adaptor-hepatitis delta virus ribozymes for use in gene targeting. Nucleic Acid Ther (2011) 0.76
Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy. J Investig Med (2014) 0.76
Specific interference shRNA-expressing plasmids inhibit Hantaan virus infection in vitro and in vivo. Acta Pharmacol Sin (2016) 0.75
Towards a genetic AIDS vaccine. Retrovirology (2009) 0.75
Achieving HIV-1 Control through RNA-Directed Gene Regulation. Genes (Basel) (2016) 0.75
SiRNA inhibits replication of Langat virus, a member of the tick-borne encephalitis virus complex in organotypic rat brain slices. PLoS One (2012) 0.75
Tongue Epithelium Cells from shRNA Mediated Transgenic Goat Show High Resistance to Foot and Mouth Disease Virus. Sci Rep (2015) 0.75
Targeting Highly Structured RNA by Cooperative Action of siRNAs and Helper Antisense Oligomers in Living Cells. PLoS One (2015) 0.75
Analysis of chikungunya virus proteins reveals that non-structural proteins nsP2 and nsP3 exhibit RNA interference (RNAi) suppressor activity. Sci Rep (2016) 0.75
Biological effects of RNAi targeted inhibiting Tiam1 gene expression on cholangiocarcinoma cells. Int J Clin Exp Pathol (2015) 0.75
Changes in the Plasticity of HIV-1 Nef RNA during the Evolution of the North American Epidemic. PLoS One (2016) 0.75
Identification of a new human coronavirus. Nat Med (2004) 11.24
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature (2012) 4.53
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2002) 3.59
Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23
HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res (2005) 2.93
Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS (2004) 2.51
Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther (2006) 2.48
The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog (2007) 2.48
Suppression of RNA interference by adenovirus virus-associated RNA. J Virol (2005) 2.29
A novel pancoronavirus RT-PCR assay: frequent detection of human coronavirus NL63 in children hospitalized with respiratory tract infections in Belgium. BMC Infect Dis (2005) 2.28
Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A (2005) 2.21
Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther (2008) 2.14
Viral evolution as a tool to improve the tetracycline-regulated gene expression system. J Biol Chem (2004) 2.06
In HIV-1 pathogenesis the die is cast during primary infection. AIDS (2007) 2.04
Croup is associated with the novel coronavirus NL63. PLoS Med (2005) 2.03
Detection of new viruses by VIDISCA. Virus discovery based on cDNA-amplified fragment length polymorphism. Methods Mol Biol (2008) 1.95
Retroviral superinfection resistance. Retrovirology (2005) 1.82
A novel long distance base-pairing interaction in human immunodeficiency virus type 1 RNA occludes the Gag start codon. J Biol Chem (2002) 1.81
Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res (2010) 1.79
Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. J Virol (2002) 1.78
The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle. J Virol (2003) 1.71
Inhibition of virus replication by RNA interference. J Biomed Sci (2003) 1.70
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci U S A (2009) 1.66
Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res (2008) 1.65
Factor correction as a tool to eliminate between-session variation in replicate experiments: application to molecular biology and retrovirology. Retrovirology (2006) 1.64
Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol (2004) 1.64
Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol (2008) 1.61
The novel human coronaviruses NL63 and HKU1. J Virol (2006) 1.59
Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol (2004) 1.53
Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol (2007) 1.52
Multiple secondary structure rearrangements during HIV-1 RNA dimerization. Biochemistry (2002) 1.50
Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference. J Virol (2007) 1.50
Microprocessor, Setx, Xrn2, and Rrp6 co-operate to induce premature termination of transcription by RNAPII. Cell (2012) 1.49
Viral immune evasion: a masterpiece of evolution. Immunogenetics (2002) 1.49
The tRNA primer activation signal in the human immunodeficiency virus type 1 genome is important for initiation and processive elongation of reverse transcription. J Virol (2002) 1.40
Mosaic structure of human coronavirus NL63, one thousand years of evolution. J Mol Biol (2006) 1.40
Proteomic studies reveal coordinated changes in T-cell expression patterns upon infection with human immunodeficiency virus type 1. J Virol (2008) 1.40
Genome structure and transcriptional regulation of human coronavirus NL63. Virol J (2004) 1.39
Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology (2013) 1.37
Human coronavirus NL63, a new respiratory virus. FEMS Microbiol Rev (2006) 1.37
Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology (2010) 1.36
The HIV-1 leader RNA conformational switch regulates RNA dimerization but does not regulate mRNA translation. Biochemistry (2005) 1.36
Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner. J Virol (2004) 1.34
Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes. J Clin Invest (2005) 1.34
Lack of detection of XMRV in seminal plasma from HIV-1 infected men in The Netherlands. PLoS One (2010) 1.34
Deep sequencing of virus-infected cells reveals HIV-encoded small RNAs. Nucleic Acids Res (2011) 1.32
A miRNA-tRNA mix-up: tRNA origin of proposed miRNA. RNA Biol (2010) 1.30
A riboswitch regulates RNA dimerization and packaging in human immunodeficiency virus type 1 virions. J Virol (2004) 1.30
Human parechovirus type 1, 3, 4, 5, and 6 detection in picornavirus cultures. J Clin Microbiol (2007) 1.28
A systematic analysis of the effect of target RNA structure on RNA interference. Nucleic Acids Res (2007) 1.27
Dimerization and template switching in the 5' untranslated region between various subtypes of human immunodeficiency virus type 1. J Virol (2003) 1.26
Comparison of single regulated lentiviral vectors with rtTA expression driven by an autoregulatory loop or a constitutive promoter. Nucleic Acids Res (2005) 1.23
Differential susceptibility of naïve, central memory and effector memory T cells to dendritic cell-mediated HIV-1 transmission. Retrovirology (2006) 1.23
The TAR hairpin of human immunodeficiency virus type 1 can be deleted when not required for Tat-mediated activation of transcription. J Virol (2007) 1.22
RNA structure modulates splicing efficiency at the human immunodeficiency virus type 1 major splice donor. J Virol (2007) 1.22
Selection of T1249-resistant human immunodeficiency virus type 1 variants. J Virol (2008) 1.21
Sialoadhesin (CD169) expression in CD14+ cells is upregulated early after HIV-1 infection and increases during disease progression. PLoS One (2007) 1.21
The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference. Retrovirology (2006) 1.20
Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr (2008) 1.20
Regulated HIV-2 RNA dimerization by means of alternative RNA conformations. Nucleic Acids Res (2002) 1.20
Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands. PLoS One (2009) 1.20
Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J Gen Virol (2006) 1.19
Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN--gp120 interaction. J Virol (2005) 1.19
RNAi suppressors encoded by pathogenic human viruses. Int J Biochem Cell Biol (2008) 1.18
Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol Ther (2009) 1.18
Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One (2009) 1.16
Effects of random mutations in the human immunodeficiency virus type 1 transcriptional promoter on viral fitness in different host cell environments. J Virol (2006) 1.16
HIV-1 latency in actively dividing human T cell lines. Retrovirology (2008) 1.16
The NS3 protein of rice hoja blanca virus complements the RNAi suppressor function of HIV-1 Tat. EMBO Rep (2009) 1.13
Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis (2012) 1.13
Inhibition of HIV-1 by fusion inhibitors. Curr Pharm Des (2010) 1.13
Probing alternative foldings of the HIV-1 leader RNA by antisense oligonucleotide scanning arrays. Nucleic Acids Res (2004) 1.12
Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J Biol Chem (2009) 1.11
SHAPE-directed discovery of potent shRNA inhibitors of HIV-1. Mol Ther (2012) 1.11
The biased nucleotide composition of the HIV genome: a constant factor in a highly variable virus. Retrovirology (2012) 1.10
Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. J Virol (2008) 1.10
The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Retrovirology (2008) 1.10
Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J Virol (2011) 1.09
Triple HIV-1 infection. N Engl J Med (2005) 1.09
Antibacterial and antiviral effects of milk proteins and derivatives thereof. Curr Pharm Des (2003) 1.08
Survey of the temporal changes in HIV-1 replicative fitness in the Amsterdam Cohort. Virology (2007) 1.08
RNAi and cellular miRNAs in infections by mammalian viruses. Methods Mol Biol (2011) 1.08
Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site. J Virol (2006) 1.07
Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother (2006) 1.07
Design of extended short hairpin RNAs for HIV-1 inhibition. Nucleic Acids Res (2007) 1.06
Dicer-independent processing of short hairpin RNAs. Nucleic Acids Res (2013) 1.06
Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure. AIDS Res Hum Retroviruses (2004) 1.06
The HIV RNA setpoint theory revisited. Retrovirology (2007) 1.06
A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs. J RNAi Gene Silencing (2005) 1.06
HIV-1 drug-resistance and drug-dependence. Retrovirology (2007) 1.05
Long-term inhibition of HIV-1 replication with RNA interference against cellular co-factors. Antiviral Res (2010) 1.05
Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs. Retrovirology (2010) 1.05
A conditionally replicating virus as a novel approach toward an HIV vaccine. Methods Enzymol (2004) 1.05
An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection. J Virol (2012) 1.04
Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. J Virol (2011) 1.04
Opposing roles of blood myeloid and plasmacytoid dendritic cells in HIV-1 infection of T cells: transmission facilitation versus replication inhibition. Blood (2006) 1.04